Loading...
RDC

Redcare Pharmacy NVXTRA:RDC Stock Report

Market Cap €1.6b
Share Price
€78.80
My Fair Value
€87.51
10.0% undervalued intrinsic discount
1Y-46.6%
7D-5.2%
Portfolio Value
​
View

Redcare Pharmacy NV

XTRA:RDC Stock Report

Market Cap: €1.6b

Redcare Pharmacy (RDC) Stock Overview

Operates the online pharmacy business in the Netherlands, Germany, Italy, Belgium, Switzerland, Austria, and France. More details

RDC fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Trading at 76.8% below our estimate of its fair value

Earnings are forecast to grow 56.32% per year

Risk Analysis

Significant insider selling over the past 3 months


RDC Community Fair Values

Create Narrative

See what 27 others think this stock is worth. Follow their fair value or set your own to get alerts.

RDC
Redcare Pharmacy

German Regulatory Updates And Digital Rx Adoption Will Transform Healthcare

Key Takeaways Regulatory changes and increasing digital adoption are strengthening competitive positioning and supporting reliable revenue growth in the expanding prescription and digital pharmacy market. Operational efficiencies and a loyal customer base are enhancing margins, while long-term demographic trends ensure stable, recurring earnings potential.
View narrative
€153.75
FV
48.7% undervalued intrinsic discount
19.09%
Revenue growth p.a.
1users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
RDC
Redcare Pharmacy

German E-Health Reforms And Fierce Competition Will Erode Market Appeal

Key Takeaways Intensifying regulatory pressures and increased competition from omnichannel rivals threaten profitability, erode market share, and challenge Redcare's digital-first positioning. Shifting healthcare policies and rising operational costs could compress margins, limit revenue growth strategies, and undermine long-term sustainability.
View narrative
€87.51
FV
10.0% undervalued intrinsic discount
15.77%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
RDC
Redcare Pharmacy

E-prescriptions And Aging Trends Will Fuel Europe's Digital Health Revolution

Key Takeaways Evolving digitalization and regulatory trends are set to drive outsized growth in Redcare's prescription revenue, margins, and overall market share well beyond current expectations. Aging population dynamics, recurring prescriptions, and expansion into digital health will strengthen customer lifetime value and unlock substantial new revenue streams.
View narrative
€214
FV
63.2% undervalued intrinsic discount
25.98%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
View Stock Community

Redcare Pharmacy NV Competitors

Price History & Performance

Summary of share price highs, lows and changes for Redcare Pharmacy
Historical stock prices
Current Share Price€78.80
52 Week High€171.40
52 Week Low€69.65
Beta0.83
1 Month Change2.34%
3 Month Change-20.00%
1 Year Change-46.65%
3 Year Change74.65%
5 Year Change-45.88%
Change since IPO177.46%

Recent News & Updates

Take Care Before Jumping Onto Redcare Pharmacy NV (ETR:RDC) Even Though It's 26% Cheaper

Sep 04
Take Care Before Jumping Onto Redcare Pharmacy NV (ETR:RDC) Even Though It's 26% Cheaper

Recent updates

Take Care Before Jumping Onto Redcare Pharmacy NV (ETR:RDC) Even Though It's 26% Cheaper

Sep 04
Take Care Before Jumping Onto Redcare Pharmacy NV (ETR:RDC) Even Though It's 26% Cheaper

Analyst Estimates: Here's What Brokers Think Of Redcare Pharmacy NV (ETR:RDC) After Its Second-Quarter Report

Aug 01
Analyst Estimates: Here's What Brokers Think Of Redcare Pharmacy NV (ETR:RDC) After Its Second-Quarter Report

Here's Why Redcare Pharmacy (ETR:RDC) Can Afford Some Debt

Jul 13
Here's Why Redcare Pharmacy (ETR:RDC) Can Afford Some Debt

Redcare Pharmacy NV (ETR:RDC) Just Released Its Annual Results And Analysts Are Updating Their Estimates

Mar 14
Redcare Pharmacy NV (ETR:RDC) Just Released Its Annual Results And Analysts Are Updating Their Estimates

Is Redcare Pharmacy (ETR:RDC) Using Too Much Debt?

Feb 27
Is Redcare Pharmacy (ETR:RDC) Using Too Much Debt?
User avatar

eRx Surge And International Expansion Poised To Elevate Revenue And Profit Margins

Rapid expansion in new markets and tech-driven efficiencies suggest future revenue growth and improved profit margins.

Here's Why Redcare Pharmacy (ETR:RDC) Can Afford Some Debt

Nov 11
Here's Why Redcare Pharmacy (ETR:RDC) Can Afford Some Debt

Is There Now An Opportunity In Redcare Pharmacy NV (ETR:RDC)?

Apr 21
Is There Now An Opportunity In Redcare Pharmacy NV (ETR:RDC)?

Are Investors Undervaluing Redcare Pharmacy NV (ETR:RDC) By 26%?

Apr 07
Are Investors Undervaluing Redcare Pharmacy NV (ETR:RDC) By 26%?

Investors Interested In Redcare Pharmacy NV's (ETR:RDC) Revenues

Mar 25
Investors Interested In Redcare Pharmacy NV's (ETR:RDC) Revenues

Redcare Pharmacy (ETR:RDC) Is Carrying A Fair Bit Of Debt

Feb 13
Redcare Pharmacy (ETR:RDC) Is Carrying A Fair Bit Of Debt

Why Investors Shouldn't Be Surprised By Redcare Pharmacy NV's (ETR:RDC) P/S

Dec 24
Why Investors Shouldn't Be Surprised By Redcare Pharmacy NV's (ETR:RDC) P/S

Is There An Opportunity With Redcare Pharmacy NV's (ETR:RDC) 48% Undervaluation?

Dec 06
Is There An Opportunity With Redcare Pharmacy NV's (ETR:RDC) 48% Undervaluation?

Is Redcare Pharmacy (ETR:RDC) Using Too Much Debt?

Sep 07
Is Redcare Pharmacy (ETR:RDC) Using Too Much Debt?

Why Redcare Pharmacy NV (ETR:RDC) Could Be Worth Watching

Aug 02
Why Redcare Pharmacy NV (ETR:RDC) Could Be Worth Watching

Why We're Not Concerned About Redcare Pharmacy NV's (ETR:RDC) Share Price

Jul 17
Why We're Not Concerned About Redcare Pharmacy NV's (ETR:RDC) Share Price

Broker Revenue Forecasts For Shop Apotheke Europe N.V. (ETR:SAE) Are Surging Higher

May 28
Broker Revenue Forecasts For Shop Apotheke Europe N.V. (ETR:SAE) Are Surging Higher

Here's Why Shop Apotheke Europe (ETR:SAE) Can Afford Some Debt

May 11
Here's Why Shop Apotheke Europe (ETR:SAE) Can Afford Some Debt

We Think Shop Apotheke Europe (ETR:SAE) Has A Fair Chunk Of Debt

Jan 10
We Think Shop Apotheke Europe (ETR:SAE) Has A Fair Chunk Of Debt

Is Shop Apotheke Europe (ETR:SAE) Using Too Much Debt?

Sep 25
Is Shop Apotheke Europe (ETR:SAE) Using Too Much Debt?

Shareholder Returns

RDCDE Consumer RetailingDE Market
7D-5.2%0.9%0.05%
1Y-46.6%11.4%12.7%

Return vs Industry: RDC underperformed the German Consumer Retailing industry which returned 11.1% over the past year.

Return vs Market: RDC underperformed the German Market which returned 12.3% over the past year.

Price Volatility

Is RDC's price volatile compared to industry and market?
RDC volatility
RDC Average Weekly Movement6.9%
Consumer Retailing Industry Average Movement6.9%
Market Average Movement5.0%
10% most volatile stocks in DE Market12.1%
10% least volatile stocks in DE Market2.4%

Stable Share Price: RDC has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: RDC's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20011,827Olaf Heinrichwww.redcare-pharmacy.com

Redcare Pharmacy NV operates the online pharmacy business in the Netherlands, Germany, Italy, Belgium, Switzerland, Austria, and France. It offers prescription and non-prescription over-the-counter pharmaceuticals, beauty and personal care products, and food supplements. The company was formerly known as Shop Apotheke Europe N.V. and changed its name to Redcare Pharmacy NV in June 2023.

Redcare Pharmacy NV Fundamentals Summary

How do Redcare Pharmacy's earnings and revenue compare to its market cap?
RDC fundamental statistics
Market cap€1.60b
Earnings (TTM)-€34.86m
Revenue (TTM)€2.68b
0.6x
P/S Ratio
-46.0x
P/E Ratio

Is RDC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RDC income statement (TTM)
Revenue€2.68b
Cost of Revenue€2.06b
Gross Profit€619.80m
Other Expenses€654.66m
Earnings-€34.86m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

Oct 29, 2025

Earnings per share (EPS)-1.71
Gross Margin23.16%
Net Profit Margin-1.30%
Debt/Equity Ratio72.8%

How did RDC perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/28 07:39
End of Day Share Price 2025/10/28 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Redcare Pharmacy NV is covered by 22 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gerhard SchwarzBaader Helvea Equity Research
Volker BosseBaader Helvea Equity Research
Alvira RaoBarclays